Erythropoiesis-Stimulating Agents (ESAs): Trends in Use in Oncology (Part 2)

Current Practices and Trends of 94 Oncologists

September 2007

Deliverable: Summary and Tabular Results of Quantitative Data

Objectives:  To understand current practices and trends regarding the use of erythropoiesis-stimulating agents (ESA) for chemotherapy-induced anemia (CIA) patients and future projected use of ESAs based on new Medicare policy.  Additionally:

§         Anticipate the impact of the Centers for Medicare and Medicaid Services (CMS) ESA coverage policy on practice patterns

§         Examine current ESA treatment methods in response to varying Hb levels and patient types

§         Determine the impact reimbursement has on ESA usage

§         Explore oncologists’ opinions on the scrutiny surrounding the use of ESAs

§         Validate prevalence of CIA by cancer type

§         Distinguish the pros and cons of using transfusion as a treatment for CIA

§         Identify drivers of brand preference and dosing patterns

Products Highlighted:

Screening Criteria:

§         US-based oncologists

§         Board-certified in specialty

§         2 to 30 years of experience post-residency

§         Minimum of 75% professional time spent in clinical practice

§         Work in a practice that manages at least 250 cancer patients in a typical month

§         Manage chemotherapy patients of which at least 25% met the clinical criteria for CIA

Reports become free one year after the publication date.